Altria Subsidiaries Challenge FDA’s 2021 PMTA Rule in Federal Lawsuit

Executive summary

Altria subsidiaries Helix Innovations and NJOY have filed a federal lawsuit against the FDA, seeking to vacate the 2021 PMTA rule on the grounds that the agency failed to meet the Tobacco Control Act’s 180-day review deadline. The complaint argues that the FDA’s prolonged review process undermines statutory compliance and creates regulatory uncertainty. The case arrives as the FDA accelerates PMTA reviews and issues more marketing orders, raising questions about procedural consistency and legal precedent.

Regulatory risk: The lawsuit could set a precedent for challenging any PMTA decision that exceeds the 180-day window, even if the delay is due to complex scientific review.

What happened

On September 2, 2026, Helix Innovations and NJOY—both subsidiaries of Altria—filed a complaint in the U.S. District Court for the District of Columbia, challenging the FDA’s 2021 PMTA rule. The core legal argument is that the agency violated Section 911 of the Tobacco Control Act, which mandates that the FDA complete its review of a PMTA application within 180 days of submission, unless the applicant requests an extension.

The complaint cites multiple instances where the FDA failed to issue final decisions within the statutory window. It references internal FDA records, government audits, and recent court rulings to demonstrate systemic delays. The plaintiffs argue that the 2021 rule, which established new review procedures, was implemented without proper adherence to the 180-day timeline, rendering it legally invalid.

The lawsuit also contends that the FDA’s current efforts to accelerate PMTA reviews—through internal reforms and expanded staffing—do not retroactively validate past noncompliance. The plaintiffs assert that the agency cannot use procedural shortcuts to justify delays that occurred during earlier review cycles.

Why it matters

This case is a pivotal test of the FDA’s procedural authority under the Tobacco Control Act. If successful, the lawsuit could invalidate the 2021 PMTA rule, which has been used as a framework for evaluating hundreds of applications. That would force the FDA to reevaluate its entire review process, potentially delaying new product approvals and increasing legal uncertainty for manufacturers.

More broadly, the case highlights a growing tension between regulatory efficiency and statutory compliance. The FDA has faced criticism for a backlog of over 1,200 PMTA applications, with many pending for years. In response, the agency has implemented reforms to speed up reviews. However, this lawsuit suggests that speed cannot come at the cost of legal adherence to the law.

Market impact

For the U.S. e-cigarette and vaping market, the outcome could be disruptive. A ruling in favor of the plaintiffs would invalidate the 2021 rule, potentially requiring the FDA to reprocess all PMTA applications reviewed under that framework. This could delay the market entry of new products, especially those from smaller brands that rely on timely approvals.

Meanwhile, larger players like Altria may gain a strategic advantage by challenging the rule’s validity. The legal action could also influence investor confidence in the regulatory environment, particularly for companies with pending PMTA applications or those planning new product launches.

Market impact: A court decision to vacate the 2021 rule could trigger a wave of legal challenges to previously approved PMTAs, increasing compliance costs and delaying product rollouts across the industry.

Regulatory impact

The lawsuit could reshape the FDA’s PMTA review system. If the court rules that the 180-day deadline is strictly enforceable—even in cases of complex scientific evaluation—it may force the agency to either meet the timeline or risk having its decisions overturned.

Conversely, if the court upholds the FDA’s current approach, it could establish a precedent allowing the agency to extend review periods without violating the law, provided it documents the reasons. This would preserve regulatory flexibility but could invite further litigation from other manufacturers.

Either outcome will influence how the FDA manages its backlog. The agency has already begun issuing more marketing orders and expanding its review teams, but the lawsuit suggests that procedural legitimacy may be as important as speed.

Who is affected

• Altria and its subsidiaries: The primary litigants, seeking to challenge a rule that may have delayed their own PMTA approvals.
• Other PMTA applicants: All manufacturers with pending or approved applications under the 2021 rule are at risk of having their status reconsidered.
• Smaller vape brands: May face disproportionate delays if the FDA is forced to reprocess applications or if legal uncertainty increases compliance costs.
• Regulatory compliance teams: Will need to reassess risk exposure related to PMTA timelines and documentation.
• U.S. federal courts: May see an uptick in challenges to FDA decisions based on procedural noncompliance.

Dawsen Take

This lawsuit is not merely a procedural dispute—it is a strategic move by a major player to reshape the regulatory landscape. By targeting the 2021 rule, Altria is challenging the legal foundation of the FDA’s current PMTA framework. The case reflects a broader industry trend: as regulatory timelines stretch, companies are turning to litigation to assert legal rights and gain competitive advantages.

The FDA’s response will be critical. If it fails to demonstrate consistent adherence to the 180-day rule, it risks undermining its own authority. But if it successfully defends the rule, it may set a precedent that allows for greater procedural flexibility in future reviews.

What to watch

Key developments to monitor include:

• The court’s ruling on the motion to dismiss or the merits of the case.
• Whether the FDA appeals a negative decision or adjusts its internal review timelines.
• Any new PMTA applications filed after the ruling and how the FDA handles them.
• Potential follow-on lawsuits from other manufacturers challenging past or current PMTA decisions.
• Changes in the FDA’s public reporting of review timelines and decision-making processes.

For more daily vaping news, check out dawsenai.com.

Original source: 2FIRSTS | Special Report | Altria Subsidiaries Sue FDA to Vacate 2021 PMTA Rule as Agency Moves to Speed Reviews